FDA-BLA761063
Document details
Summary
Emgality (galcanezumab) is likely to receive a new J-code for billing under Medicare Part B since it is an injectable drug. The drug may be eligible for ASP+6% reimbursement, given its injectable statNew injectable drug Emgality poised for Medicare billing impact.
Affected specialty
Neurology alerts →Source document
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761063s000lbl.pdfCLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-BLA125360 · Neurology
Xeomin (incobotulinumtoxinA) is an injectable botulinum toxin type A administered via injection, placing it squarely in the Medicare Part B pathway for physician-administered drugs. It is reimbursed u
View alertPolicy FDA-BLA761149 · Neurology
Enspryng (Satralizumab) is an injectable drug approved for Part B billing, likely leading to a new J-code assignment. With its status as an orphan drug, it may qualify for pass-through payment under M
View alertPolicy FDA-BLA761119 · Neurology
VYEPTI (Eptinezumab-JJMR) is an injectable medication likely to receive a J-code for billing under Medicare Part B. Its category may allow for ASP+6% reimbursement, but billing teams should confirm th
View alertPolicy FDA-NDA210365 · Neurology
Epidiolex, an oral cannabidiol solution, will fall under Medicare Part D for billing purposes. As it is an orphan drug, it may also have specific considerations for reimbursement and coverage. No J-co
View alert